Ansbert Gadicke Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $1.43, for a total transaction of $124,318.48. Following the transaction, the insider directly owned 6,355,717 shares in the company, valued at $9,088,675.31. This represents a 1.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Price Performance

Shares of HOWL stock remained flat at $1.31 during mid-day trading on Monday. 712,892 shares of the stock traded hands, compared to its average volume of 494,803. The stock has a market capitalization of $59.91 million, a P/E ratio of -0.80 and a beta of 0.73. The company has a 50-day simple moving average of $1.62 and a 200 day simple moving average of $1.32. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.52.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. On average, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $409,000. Marshall Wace LLP acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $113,000. Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $92,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at $79,000. Finally, Nuveen LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at $71,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Bank of America cut their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.